文献速递肿瘤 PET/CT核素与放射性配体治疗

一种靶向CEACAM5的纳米抗体用于结直肠癌的正电子发射断层显像与近红外荧光成像

Identification of a CEACAM5 targeted nanobody for positron emission tomography imaging and near-infrared fluorescence imaging of colorectal cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-03-14

本研究旨在鉴定靶向CEACAM5的纳米抗体,并验证其在结直肠癌(CRC)正电子发射断层显像(PET)和近红外(NIR)荧光成像中的应用。研究通过免疫骆驼和噬菌体筛选获得纳米抗体Nb41,并进行18F放射标记和IR800荧光标记,在CRC皮下移植瘤和淋巴结转移模型中进行成像。结果显示CEACAM5在CRC组织和转移淋巴结中过表达,18F-FB-Nb41和18F-FB-Nb41-ABD在肿瘤和淋巴结转移灶中均有明显富集,IR800偶联的纳米抗体在皮下模型中显示优异成像效果。

要点

  • CEACAM5在结直肠癌组织和转移淋巴结中过表达。
  • 成功获得靶向CEACAM5的纳米抗体Nb41,且融合白蛋白结合域(ABD)不影响其亲和力。
  • 18F-FB-Nb41和18F-FB-Nb41-ABD在肿瘤和淋巴结转移灶中均有明显富集,Nb41-ABD-IR800在肿瘤中荧光强度更高但延迟更明显。

核心结论

  • 研究鉴定并体内验证了一种靶向CEACAM5的纳米抗体及其与ABD融合的纳米抗体,可在皮下模型和淋巴结转移模型中用PET和NIR成像对结直肠癌恶性病变进行无创可视化。

研究设计与样本

  • 研究采用免疫骆驼获取CEACAM5靶向纳米抗体,经多轮噬菌体筛选,并用免疫荧光染色和流式细胞术测定结合亲和力。
  • 纳米抗体通过偶联18F-SFB进行放射标记用于PET成像,IRDye800CW(IR800)偶联形成NIR探针用于近红外成像。
  • 成像模型包括结直肠癌皮下移植瘤和淋巴结转移模型。

主要发现

  • CEACAM5在人结直肠癌组织和转移淋巴结中过表达。
  • 成功生成靶向CEACAM5的纳米抗体Nb41,具有优异的体外结合特性,融合白蛋白结合域(ABD)不影响Nb41的亲和力。
  • 18F-FB-Nb41和18F-FB-Nb41-ABD在肿瘤中均有明显富集,由于18F-FB-Nb41-ABD在血液中滞留时间更长,其在肿瘤中的富集显著延迟但高于18F-FB-Nb41。
  • 18F-FB-Nb41和18F-FB-Nb41-ABD在淋巴结转移灶中均有显著富集。
  • IR800偶联的Nb41-IR800和Nb41-ABD-IR800在皮下模型中均显示优异成像效果,Nb41-ABD-IR800在肿瘤中荧光强度更高,但较Nb41-IR800明显延迟。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Here, we aim to identify a CEACAM5-targeted nanobody and demonstrate its application in positron emission tomography (PET) imaging and near-infrared (NIR) fluorescence imaging in colorectal cancer (CRC). METHODS: Immunohistochemistry was applied to verify CEACAM5 expression in CRC and metastatic lymph nodes (mLNs). CEACAM5-targeted nanobodies were obtained by immunization of human CEACAM5 protein in a dromedary, followed by several rounds of phage screenings. Immunofluorescence staining and flow cytometry was carried out to determine the binding affinity of the nanobodies. The nanobodies were radiolabeled by coupling 18F-SFB for PET imaging of CRC subcutaneous xenografts and lymph node metastasis (LNM). IRDye800CW (IR800) were conjugated to form NIR probes for NIR imaging in CRC subcutaneous models. RESULTS: CEACAM5 was overexpressed in either human CRC tissues or mLNs. A CEACAM5 targeted nanobody, Nb41 was successfully generated, with excellent in vitro binding properties. Incorporation of albumin binding domain (ABD) did not affect the affinity of Nb41. In vivo imaging showed that both 18F-FB-Nb41 and 18F-FB-Nb41-ABD showed obvious accumulation in the tumor. Due to the longer retention in the blood, 18F-FB-Nb41-ABD enrichment in tumors was significantly delayed but higher compared to 18F-FB-Nb41. Both 18F-FB-Nb41 and 18F-FB-Nb41-ABD showed prominent LNM enrichment. Similarly, the IR800-conjugated nanobodies Nb41-IR800 and Nb41-ABD-IR800 exhibited superior imaging effects in subcutaneous models, while Nb41-ABD-IR800 exhibited higher fluorescence intensity in the tumor accompanied with a remarkedly delay compared to Nb41-IR800. CONCLUSION: Collectively, we presented the identification and in vivo validation of a CEACAM5-targeted nanobody and a fused nanobody with an ABD, which enabled to the non-invasive visualization of malignancy of CRC using PET imaging and NIR imaging in subcutaneous models as well as LNM models.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Xiao Y, Mei C, Xu D, et al. Identification of a CEACAM5 targeted nanobody for positron emission tomography imaging and near-infrared fluorescence imaging of colorectal cancer. Eur J Nucl Med Mol Imaging. 2023. PMID: 36914753. doi:10.1007/s00259-023-06183-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。